CHATSWORTH, Calif.--(BUSINESS WIRE)--April 25, 2006--North American Scientific, Inc. (Nasdaq:NASI - News), a leading manufacturer of brachytherapy sources, announced today that the Company has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the low-dose rate radiation treatment design of its recently announced breast brachytherapy product. The product is designed to enhance current accelerated partial breast irradiation (APBI) treatment options, an estimated $500 million U.S. market.
